Please assess the completion status of the following clinical trial:

Trial Title: A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Be of Japanese descent, defined as born in Japan and having Japanese parents and Japanese maternal and paternal grandparents.~* Participants must have a documented diagnosis of a form of primary humoral immunodeficiency involving antibody formation and requiring gammaglobulin replacement. The diagnosis must be confirmed by the medical director prior to treatment with IGIV.~* Participant is 2 years or older at the time of screening.~* Written informed consent is obtained from either the participants or the participants legally authorized representative prior to any study-related procedures and study product administration.~* Participant has been receiving a consistent dose of IGIV over a period of at least 3 months prior to screening equivalent to approximately 200-600 mg/kg-body weight (BW) per 3- 4 week period, as according to the product package insert~* Participant has a serum trough level of IgG \>= 5 gram per liter (g/L) at screening.~* Participant has not had a serious bacterial infection within the 3 months prior to screening.~* Participant is willing and able to comply with the requirements of the protocol.~Exclusion Criteria:~* Participant has a known history of or is positive at screening for one or more of the following: hepatitis B surface antigen (HBsAg), polymerase chain reaction (PCR) for hepatitis C virus (HCV), PCR for human immunodeficiency virus (HIV) Type 1/2.~* Abnormal laboratory values at screening meeting any one of the following criteria (abnormal tests may be repeated once to determine if they are persistent):~  * Persistent alanine aminotransferase (ALT) and aspartate amino transferase (AST) \> 2.5 times the upper limit of normal (ULN) for the testing laboratory~ * Persistent severe neutropenia (defined as an absolute neutrophil count \[ANC\] \<= 500/milli cubic meter \[mm\^3\]).~* Participant has presence of renal function impairment defined by estimated glomerular filtration rate (eGFR) is \<60 milliliter per minute/ 1.73 square meter (mL/min/1.73m\^2).~* Participant has been diagnosed with or has a malignancy (other than adequately treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix), unless the disease-free period prior to screening exceeds 5 years.~* Participant is receiving anti-coagulation therapy or has a history of thrombotic episodes (including deep vein thrombosis, myocardial infarction, cerebrovascular accident, pulmonary embolism) within 12 months prior to screening or a history of thrombophilia.~* Participant has abnormal protein loss (protein losing enteropathy, nephrotic syndrome).~* Participant has anemia that would preclude phlebotomy for laboratory studies according to standard practice at the site.~* Participant has an ongoing history of hypersensitivity or persistent reactions (urticaria, breathing difficulty, severe hypotension, or anaphylaxis) following IV immunoglobulin, SC immunoglobulin, and/or Immune Serum Globulin (ISG) infusions.~* Participant has immunoglobulin A (IgA) deficiency (IgA less than 0.07 g/L), known anti IgA antibodies, and a history of hypersensitivity.~* Participant is on preventative (prophylactic) systemic antibacterial antibiotics at doses sufficient to treat or prevent bacterial infections, and cannot stop these antibiotics at the time of screening.~* Participant has active infection and is receiving antibiotic therapy for the treatment of infection at the time of screening.~* Participant has a bleeding disorder, or a platelet count less than 20,000/ microliter (mcL), or, in the opinion of the investigator, would be at significant risk of increased bleeding or bruising as a result of subcutaneous therapy.~* Participant has total protein \> 9 gram per deciliter (g/dL) or myeloma, or macroglobulinemia (IgM) or paraproteinemia.~* Women of childbearing potential meeting any one of the following criteria:~  * Participant presents with a positive pregnancy test.~ * Participant is breast feeding.~ * Participant intends to begin nursing during the course of the study.~ * Participant does not agree to employ adequate birth-control measures (e.g. intrauterine device, diaphragm or condom \[for male partner\] with spermicidal jelly or foam, or birth control pills/patches) throughout the course of the study.~* Participant has participated in another clinical study and has been exposed to an IP or device within 30 days prior to study enrollment.~* Participant is scheduled to participate in another non-observational (interventional) clinical study involving an IP or device during the course of the study.~* Participant has severe dermatitis that would preclude adequate sites for safe product administration.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Epoch 1: IGIV 200-600 mg/kg (Type: EXPERIMENTAL): Participants received 200 to 600 mg/kg of Immunoglobulin Intravenous (IGIV) infusion for every 3 or 4 weeks for up to 13 weeks.
- Epoch 2: IGSC (20%) 50-200 mg/kg (Type: EXPERIMENTAL): Participants who entered to Epoch 2 from Epoch 1 received 50-200 mg/kg of Immune Globulin Subcutaneous (Human) 20% infusion once a week up to approximately 24 weeks after Epoch 1.
- Epoch 3: IGSC (20%) 100-400 mg/kg (Type: EXPERIMENTAL): Participants who entered to Epoch 3 from Epoch 1 received 100-400 mg/kg of Immune Globulin Subcutaneous (Human) 20% infusion biweekly up to approximately 12 weeks after Epoch 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).